ArticleThe Medical journal of Australia2021
Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020.
Article in The Medical journal of Australia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of infection and transmission of SARS-CoV-2 among children and adolescents in households, communities and educational settings: A systematic review and meta-analysis.Journal of global health · 2021Pooled it
- Article
- Higher uptake of common adult vaccines in Australian blood donors: An analysis of linked registry data.Vox sanguinis · 2026Article
- Article
- Characteristics and predictors of severe outcomes of COVID-19 cases presenting to the emergency department of a major Australian referral hospital: A record linkage study.Emergency medicine Australasia : EMA · 2025Article
- A data science pipeline applied to Australia's 2022 COVID-19 Omicron waves.Infectious Disease Modelling · 2025Article
- Assessing the effects of SARS-CoV-2 vaccination on the risk of household transmission during delta variant circulation: a population-based data linkage cohort study.The Lancet regional health. Western Pacific · 2024Article
- The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A cross-sectional study.PloS one · 2024Article
- Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.PloS one · 2023Article
- Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020-July 2021.Vaccines · 2022Article
- The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021.The Medical journal of Australia · 2022Article
- A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.Journal of medical virology · 2022Article
- Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia After the First Epidemic Wave in 2020: A National Survey.Open forum infectious diseases · 2022Article
- Article
- Article
- Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020.PloS one · 2022Article
- The utility of SARS-CoV-2-specific serology in COVID-19 diagnosis.Australian and New Zealand journal of public health · 2021Article
- SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.Viruses · 2021Article
- SARS-CoV-2 seroprevalence in healthcare workers in a tertiary healthcare network in Victoria, Australia.Infection, disease & health · 2021Article
- Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand.Epidemiology and infection · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesTo estimate SARS-CoV-2-specific antibody seroprevalence after the first epidemic wave of coronavirus disease 2019 (COVID-19) in Sydney. SETTING,
participantsPeople of any age who had provided blood for testing at selected diagnostic pathology services (general pathology); pregnant women aged 20-39 years who had received routine antenatal screening; and Australian Red Cross Lifeblood plasmapheresis donors aged 20-69 years.
designCross-sectional study; testing of de-identified residual blood specimens collected during 20 April - 2 June 2020.
main outcome measureEstimated proportions of people seropositive for anti-SARS-CoV-2-specific IgG, adjusted for test sensitivity and specificity.
resultsThirty-eight of 5339 specimens were IgG-positive (general pathology, 19 of 3231; antenatal screening, 7 of 560; plasmapheresis donors, 12 of 1548); there were no clear patterns by age group, sex, or location of residence. Adjusted estimated seroprevalence among people who had had general pathology blood tests (all ages) was 0.15% (95% credible interval [CrI], 0.04-0.41%), and 0.29% (95% CrI, 0.04-0.75%) for plasmapheresis donors (20-69 years). Among 20-39-year-old people, the age group common to all three collection groups, adjusted estimated seroprevalence was 0.24% (95% CrI, 0.04-0.80%) for the general pathology group, 0.79% (95% CrI, 0.04-1.88%) for the antenatal screening group, and 0.69% (95% CrI, 0.04-1.59%) for plasmapheresis donors.
conclusionsEstimated SARS-CoV-2 seroprevalence was below 1%, indicating that community transmission was low during the first COVID-19 epidemic wave in Sydney. These findings suggest that early control of the spread of COVID-19 was successful, but efforts to reduce further transmission remain important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.